


Brian Hurley, M.D., M.B.A., DFASAM, FAPA


No financial conflicts of interests


Brian is the President of the American Society of Addiction Medicine, so comments on topics involving ASAM (which maintains a <u>Treatment in Correctional Settings Toolkit</u> among other training products and practice guidelines)

may be biased towards ASAM

None of the medications discussed in this presentation are FDA approved for Stimulant Use Disorders








Carceral Settings


- 65% percent of the incarcerated population in the US has an active substance use disorder.
- Another 20% percent does not meet the official criteria for a substance use disorder, but were under the influence of drugs or alcohol at the time of their crime.
- For those in jail, regular use of <u>opioids</u> was reported at 17 percent.
- Up to 20% of individuals housed within prison in the United States meet criteria for <u>opioid</u> use disorder.

Center on Addiction, Behind Bars II: Substance Abuse and America's Prison Population, February 2010. https://www.centeronaddiction.org/addiction-research/reports/behind-bars-ii-substance-abuse-and-america's-prison-population

Bronson, J., Stroop, J., Zimmer, S., & Berzofsky, M. (2017). Drug Use, Dependence, and Abuse Among State Prisoners and Jail Inmates, 2007-2009. NCJ 250546. Washington, DC: Bureau of Justice Statistics Lo CC, Stephens RC. Drugs and prisoners: treatment needs on entering prison. Am J Drug Alcohol Abuse. 2000;26(2):229–45.

Fazel S, Bains P, Doll H. Substance abuse and dependence in prisoners: a systematic review. Addiction. 2006;101(2):181–91.





Carceral Settings


- High risk of overdose in the period immediately following release from custody. Post-release overdose is the <u>leading</u> <u>cause of death</u> among people released from jails or prisons.
- People who have been incarcerated are at risk of death from overdose >100 times greater than the general population.
- Risk is highest in the two weeks after release.


Joudrey, P. J., Khan, M. R., Wang, E. A., Scheidell, J. D., Edelman, E. J., McInnes, D. K., & Fox, A. D. (2019). A conceptual model for understanding post-release opioid-related overdose risk. *Addiction science & clinical practice*, *14*(1), 17.


Binswanger IA, Stern MF, Deyo RA, Heagerty PJ, Cheadle A, Elmore JG, et al. Release from prison—a high risk of death for former inmates. N Engl J Med. 2007;356(2):157–65.


Binswanger IA, Blatchford PJ, Mueller SR, Stern MF. Mortality after prison release: opioid overdose and other causes of death, risk factors, and time trends from 1999 to 2009. Ann Intern Med. 2013;159(9):592–600.


Grella CE, Ostlie E, Scott CK, Dennis ML, Carnevale J, Watson DP. A scoping review of factors that influence opioid overdose prevention for justice-involved populations. Subst Abuse Treat Prev Policy. 2021 Feb 22;16(1):19. doi: 10.1186/s13011-021-00346-1. PMID: 33618744: PMCID: PMC7898779.















Bottom Line


Nobody needs to die from an opioid overdose













Reasons Cited for Not Seeking Treatment

- Should be able to handle alcohol / drug use on own (74.1%)
- Not being ready to start treatment (65.6 %)
- Not being ready to stop or cut back (60.1%)
- Being worried about what people would think or say (43.9%)
- Thinking treatment would cost too much (42.4%)
- Not having enough time for treatment (41.0%);
- Not knowing how or where to get treatment (38.%);
- Worried information would not be kept private (34.8%);
- Bad things would happen if people knew (33.5%)
 - Losing job, home, or children
- Health insurance would not pay enough treatment costs (31.9%)

Substance Abuse and Mental Health Services Administration. (2024). Key substance use and mental health indicators in the United States: Results from the 2023 National Survey on Drug Use and Health (HHS Publication No. PEP24-07-021, NSDUH Series H-59). Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services
Administration. http://www.saminsa.gov/data/report/2023-nsduh-annual-national-report

8/4/2024

Table 1 **Comparison of Penetration and Engagement Rates** for Members Transitioning from Incarceration in FY 2018-19 and FY 2019-20 with Any Type of Behavioral Health Services by Behavioral Health Need Penetration **Engagement** FY 2019-20 FY 2019-20 FY 2018-19 FY 2018-19 % (+/-) % (+/-) **Behavioral Health Need** -3% +5% 30% 27% 16% 21% **SUD Only** 56% -5% 35% 41% +6% Co-Occurring 51% 55% 50% -5% 36% 41% +5% Mental Health Only

• Penetration rate of mental health needs > SUD needs

Council on Criminal Justice and Behavioral Health. Medi-Cal Utilization Project: A Report on the Medi-Cal Enrollment and Behavioral Health Services Utilization for Individuals Released from the California Department of Corrections and Rehabilitation in Fiscal Year 2019-20. October 2023. http://www.cdcr.ca.gov/ccjbh/wp-content/uploads/sites/172/2024/01/MCUP-FY-2019-2020-October-2023-ADA-1.pdf

23

Table 2 Penetration and Engagement Rates in Behavioral Health Services By Behavioral Health Need and Medi-Cal Behavioral Health Service Type for Members Transitioning from Incarceration in FY 2019-20							
Medi-Cal Behavioral Health Service Type	# of Services	SUD Only		ehavioral Health Ne Co-Occurring		ed Mental Health Only	
		n	%	n	%	n	%
Medi-Cal SUD	1+	2,898	19%	1,434	29%	451	23%
	5+	2,295	15%	955	19%	290	15%
	Total Enrolled	14,973	100%	4,952	100%	1,958	100%
SMHS	1+	1,122	7%	1,462	30%	681	35%
	5+	859	6%	1,177	24%	574	29%
	Total Enrolled	14,973	100%	4,952	100%	1,958	100%
Non-SMHS	1+	1,313	9%	1,189	24%	420	21%
	5+	479	3%	471	10%	154	8%
	Total Enrolled	14,973	100%	4,952	100%	1,958	100%


Council on Criminal Justice and Behavioral Health. Medi-Cal Utilization Project: A Report on the Medi-Cal Enrollment and Behavioral Health Services Utilization for Individuals Released from the California Department of Corrections and Rehabilitation in Fiscal Year 2019-20. October 2023. http://www.cdcr.ca.gov/ccjbh/wp-content/uploads/sites/172/2024/01/MCUP-FY-2019-2020-October-2023-ADA-1.pdf


Surgeon General's Report




<u>Integrating</u> substance use services results in better outcomes

https://addiction.surgeongeneral.gov/









SAMHSA Principles of Low Barrier Models of Care

- Person-centered care
- Harm reduction and meeting the person where they are
- Flexibility in service provision
- Provision of comprehensive services
- Culturally responsive and inclusive care
- · Recognize the impact of trauma

http://store.samhsa.gov/product/advisory-low-barrier-models-care-substance-use-disorders/pep23-02-00-005

29

29



SAMHSA Components of Low Barrier Models of Care

- · Available and accessible
- Flexible
- Responsive to patient needs
- Collaborative with community based organizations
- Engaged in learning and quality improvement

 $\underline{http://store.samhsa.gov/product/advisory-low-barrier-models-care-substance-use-disorders/pep23-02-00-005}$

Barrier Level	Requirements and Approach 35,36,37,38,39,40	Requirements and Approach (medication only)	Availability ^{41,42,43,44,45}
Low Barrier Care	No service engagement conditions or preconditions. Visit frequency based on clinical stability. Ongoing substance use does not automatically result in treatment discontinuation. Client's individual recovery goals prioritized. Reduction in substance use and engaging in less risky substance use as acceptable goals.	Medication at first visit. Home initiation permitted. Various medication formulations offered. Individualized medication dosage. Rapid re-initiation of medication after short-term disruption.	Treatment available in non-specialty SUD settings. Other clinical and non-clinical services incorporated into SUD treatment settings. Same-day treatment availability, no appointment required. Extended hours of operation. Telehealth and in-person services available.
High Barrier Care	Requirements for current or previous engagement with specific services. Visit frequency based on a rigid, pre-determined schedule. Treatment discontinuation due to ongoing substance abuse. Treatment goals imposed. Absti	Two or more visits before medication. Clinic initiation required. Limited medication formulation options. Uniform maximum dosage. Induction required to restart medication.	Treatment only available at specialty SUD programs. Non-integrated or limited-service offerings. One or more day wait to initiate treatment, appointment required. Traditional hours of operation. Services only available in-



Reaching the 95% (R95) Initiative

- Fundamentally, we need to take a different approach to address SUDs to substantively increase our reach into the 95% and increase our treatment penetration rates.
- Data demonstrates that we will be unlikely to substantively increase the people we serve without focusing on engaging this 95%.
- The R95 Initiative was launched by the Los Angeles County Department of Public Health's Substance Abuse Prevention and Control (DPH-SAPC) in 2023 to focus on needed CULTURE CHANGE WITHIN THE SPECIALTY SUD SYSTEM to shape the way that we think about and treat those with SUD.
 - Key Goals
 - 1. Optimizing Outreach & Engagement
 - 2. Establishing Lower Barriers to SUD Care



Expanding Reach

- DPH-SAPC operates the <u>specialty</u> SUD system
 - While specialists are important in care delivery, they are not the only
 providers of care and it's important to enlist a broad network of entities
 to help ensure access to needed services (primary care, caregivers, etc).
- With a condition such as SUD where most of the people with the condition aren't seeking
 out services, we need to leverage every possible avenue to help engage people with SUD,
 most importantly those who spend the most time with them.
 - -e.g., housing providers, primary case managers outside the SUD system, teachers, caregivers, primary care, etc.

Specialty SUD Providers : SUD

Cardiology : High blood pressure or cholesterol

Endocrinology : Diabetes

33

33



Implicit bias

Attitudes or stereotypes that affect our understanding, actions, and decisions in an unconscious manner

A group of researchers used a "Go-No Go" task to test implicit bias (positive or negative response) toward language used for substance use disorders

Ashford, RD, Brown. AM & Curtis, B (2018): The Language of Substance Use and Recovery: Novel Use of the Go/No–Go Association Task to Measure Implicit Bias. Health Communication.

Slide Credit: UCLA ISAP (Freese, Hasson, Hovik, Kurtz, Peck, Rutkowski)



Findings

Negative

- Substance Abuser
- Relapse
- Medication-Assisted Treatment
- Overdose
- Addict
- Alcoholic
- Opioid Addict

Positive

- Person who uses substances
- Recurrence of use
- Pharmacotherapy
- Accidental drug poisoning
- Person with a substance use disorder.

Slide Credit: UCLA ISAP (Freese, Hasson, Hovik, Kurtz, Peck, Rutkowski)


35





Recommendations


- Avoid labeling
- Receive training to help you become aware of unconscious biases and increase your knowledge and understanding.
- Use person first language (avoid stigmatizing language)
- Create an atmosphere that is supportive with zero tolerance for discrimination.
- Acknowledge patients' significant others and encourage their support and participation in prevention and treatment programs.


Slide Credit: UCLA ISAP (Freese, Hasson, Hovik, Kurtz, Peck, Rutkowski)











Why Not Detoxification?

POST-DETOXIFICATION RELAPSE RATES APPROACH 100% WITHIN THE FIRST 90 DAYS FOLLOWING COMPLETION OF DETOXIFICATION.



Slide Credit: Larissa Mooney, M.D.

Incarcerated Individuals

•77 percent of incarcerated individuals with an OUD relapse to opioid use within three months of release (even after participating in a counseling program) without addiction medications.

SAMHSA (2019). Medication-Assisted Treatment (MAT) in the Criminal Justice System: Brief Guidance to the States.

http://store.samhsa.gov/product/Medication-Assisted-Treatment-MAT-in-the-Criminal-Justice-System-Brief-Guidance-to-the-States/PEP19-MATBRIEFCJS

43



Medication FIRST Model

- People with OUD receive pharmacotherapy treatment as quickly as possible, prior to lengthy assessments or treatments planning sessions;
- Maintenance pharmacotherapy is delivered without arbitrary tapering or time limits;
- Individualized psychosocial services are continually offered but not required as a condition of pharmacotherapy;
- Pharmacotherapy is discontinued only if it is worsening the person's condition.


http://www.nomodeaths.org/medication-first-implementation




Medication FIRST Model


- Medication first does not mean Medication only
- Medication is contingent upon the pt's benefit, not based upon a timeframe, patient's participation in counseling, an unexpectedly positive test result, etc

http://www.nomodeaths.org/medication-first-implementation



Buprenorphine Formulations for Opioid Use Disorder								
Content	Route	Products	Available Doses	Equivalent Dose to 8mg Buprenorphine				
With Naloxone	Sublingual	Film (suboxone)	2mg Bup/0.5mg Nx 4mg Bup/1mg Nx 8mg Bup/2mg Nx 12mg Bup/3mg Nx	8mg				
		Tablet - Generic	2mg Bup/0.5mg Nx 8mg Bup/2mg Nx					
	Sublingual	Tablet - (Zubsolv®)	1.4mg Bup / 0.36mg Nx 2.9mg Bup / 0.7mg Nx 5.7mg Bup / 1.4mg Nx 8.6mg Bup / 2.1mg Nx 11.4mg Bup / 2.6mg Nx	5.7 mg				
	Buccal	Film (Bunavail®)	2.1mg Bup / 0.3mg Nx 4.2mg Bup / 0.7mg Nx 6.3mg Bup / 1mg Nx	4.2mg				
Mono- product	Sublingual	Tablet - Generic	2mg Bup 8mg Bup	8mg				
	mpiane	ртоварінне	(Favoring lasts favoring	-74.2 mg.				
	Injection	sublocade	100mg, 300mg (Once-monthly injection)	300 mg: First dose 100mg: Steady state dose				







ER Buprenorphine Injection

Advantages

- Only once per month
 - Less staff needed to administer compared to a daily controlled med
 - Patients will be protected when they leave jail to the community
 - Better adherence
- Eliminates diversion


Disadvantages


- Pain from Injection
- Less popular with patients


51

Follow up

- Generally well-tolerated
 - "Thank you for giving me this treatment!"
- Possible complaints
 - Irritation at injection site, "allergic reaction"
 - Persistent pain
 - Withdrawal/cravings
 - Urinary retention
 - Fatigue
 - "I need to switch back to suboxone"









In Opioid Use Disorder:
Adding psychosocial support does not change the effectiveness of retention in treatment and opiate use during treatment.

Amato L, Minozzi S, Davoli M, Vecchi S. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database of Systematic Reviews 2011, Issue 10. Art. No.: CD004147. DOI: 10.1002/14651858.CD004147.pub4




Alcohol Use Disorder (AUD) Pharmacotherapy


Medications for AUD have different mechanisms of action:


- Discourage drinking by creating unpleasant association with alcohol
 - Aversive effect (i.e. "punishment")
- · Block or reduce euphoria from alcohol
 - Reduce positive reinforcement
- Reduce post-acute withdrawal
 - Negative reinforcement




Slide Credit: Larissa Mooney, M.D.














Contingency Management (CM)

- Key Concepts
 - Behavior to be modified (e.g. stimulant use) must be objectively measured
 - Behavior to be modified (e.g. urine toxicology tests) must be monitored frequently
 - · Reinforcement must be immediate
 - Penalties for unsuccessful behavior (e.g. +UDS) include withholding the reinforcer

 $\underline{http://www.dhcs.ca.gov/Pages/DMC-ODS-Counties-Participating-in-the-Incentives-Recovery-Program.aspx}$





Medications for Stimulant Use Disorder (MAT for StimUD)


- Pharmacotherapies, including psychostimulant medications, may be utilized offlabel to treat StUD.
- When prescribing controlled medications, clinicians should closely monitor patients and perform regular ongoing assessment of risks and benefits for each patient.
- Psychostimulant medications should only be prescribed to treat StUD by:
 - Physician specialists who are board certified in addiction medicine or addiction psychiatry; and
 - Physicians with commensurate training, competencies, and capacity for close patient monitoring.


65



Medications for Methamphetamine Use Disorder (none are FDA approved for the indication of StimUD)

- ER Naltrexone injection and high dose bupropion
- Mirtazapine (two small studies)
- Bupropion (low-level users who will adhere)
- Topiramate (low-level users)
- Methylphenidate (moderate to high dose in frequent users/those with ADHD)









Medications for Cocaine Use Disorder (none are FDA approved for the indication of StimUD)

- Bupropion (works best when combined with CM)
- Topiramate (low-level users)
- Modafinil (if the client does not have alcohol use disorder)
- Combination of Mixed Amphetamine Salts-Extended Release and Topiramate
- Mixed Amphetamine Salts-Extended Release










Residential Treatment and Length of Stay

- Longer time in treatment → better treatment outcomes¹
- It is <u>not</u> duration of *residential treatment* per se that is associated with reduced relapse risk
- Rather: matching characteristics of the patients to the level of care that best meets their needs for as long as they need it
- Residential SUD treatment should be as long as medical necessary
 - Medical necessity is based on ASAM Criteria
- For adults in LA County, DPH-SAPC authorizes an initial 60 days of residential treatment that can be renewed every 30 days based upon the patient meeting medical necessity for ongoing residential treatment. There is no absolute cap on the duration of residential treatment.

^{1.} Andersson HW, Wenaas M, Nordfjærn T. Relapse after inpatient substance use treatment: A prospective cohort study among users of illicit substances. Addict Behav. 2019 Mar;90:222-228. doi: 10.1016/j.addbeh.2018.11.008. Epub 2018 Nov 11. PMID: 30447514.











SUD Treatment Referral Line



- (800) 879-2772 Statewide Toll-Free, or
- (916) 327-3728 Outside California

OR

- Directory of County SUD Referral Lines
 - http://www.dhcs.ca.gov/individuals/Pages/SUD_County_Access_Lines.aspx

77

77

Recover LA Mobile App



- · Free mobile app
- Provides education and resources for those seeking substance use services for themselves or others
- Available in 13 languages
- RecoverLA.org

QR code can be used to access the app as well






X



Service & Bed Availability Tool (SBAT) **Service & Bed Availability Tool** (SBAT) at www.SUDHelpLA.org → find SUD treatment services, beds, and site contact information. Filter by: Distance Treatment/Service Type Languages Spoken Clients Served (e.g. youth, perinatal, disabled, LGBTQIA, homeless, re-entry, etc.) Night/Weekend availability www.SUDHelpLA.org 80







Key Take Home Points

- Everyone gets naloxone
- Language matters
- Lack of demand > Lack of supply of formal specialty substance use treatment
 - 95% of people don't get specialty SUD treatment (because they are not interested in treatment as usual)

- Don't assume the goal of abstinence initially
 - The 95%!
- Offer Medications for Addiction Treatment
 - Particularly for Opioid Use Disorder
 - · As quickly as possible
 - Without unnecessary contingencies

83

83



Questions?

Brian Hurley, M.D., M.B.A., FAPA, DFASAM bhurley@ph.lacounty.gov

Interested in more? Come to:

*ASAM Annual Meeting CSAM Annual Meeting (Denver in April 2025!) (San Francisco Aug 2024!) (Naples, FL Nov 2024!) (Naples, FL Nov 2024!) (http://www.asam.org http://csam-asam.org http://www.aaap.org